Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06339788
Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05688098
- Locations
- π°π·
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05688085
- Locations
- π°π·
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05663073
- Locations
- π°π·
H Plus Yangji Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 208
- Registration Number
- NCT05504226
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT05504239
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 271
- Registration Number
- NCT05476354
- Locations
- π°π·
Severance Hospital, Seoul, Korea, Republic of
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT05475665
- Locations
- π°π·
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea
- Conditions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05405777
A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
Completed
- Conditions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05337683
- Locations
- π°π·
Handok, Seoul, Korea, Republic of
Β© Copyright 2024. All Rights Reserved by MedPath